NCT04425265 Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
| NCT ID | NCT04425265 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sun Yat-sen University |
| Condition | Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2020-06-30 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2020-06-30 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims at exploring whether plasma radiofrequency ablation at low temperature is associated with better survival outcome in localized recurrent nasopharyngeal carcinoma by conducting a randomized controlled trial of plasma radiofrequency ablation at low temperature versus electrocautery block resection at high frequency for localized recurrent nasopharyngeal carcinoma. If the hypothesis is confirmed, it is expected to provide a convenient choice for the surgical treatment of localized recurrent nasopharyngeal carcinoma.
Eligibility Criteria
Inclusion Criteria: 1. At least 6 months disease free interval (defined as duration between the initial course of radiotherapy and recurrence) 2. Histopathologically diagnosed with undifferentiated or differentiated, nonkeratinizing nasopharyngeal carcinoma. 3. Resectable recurrent nasopharyngeal carcinoma: rT1-3N0-3M0 A) The tumor is confined to the nasopharyngeal mucosa, or the surface of the parapharyngeal space, or the bottom wall of the sphenoid sinus, and is more than 0.5cm away from the internal carotid artery B) The cervical lymph node lesions do not infiltrate the cervical spine, brachial plexus, cervical muscles, and internal carotid artery. 4. Age: 18-70 years old. 5. Subjects must sign an informed consent form. Exclusion Criteria: 1. Karnofsky score (KPS)≤70. 2. Has known Subjects with other malignant tumors. 3. Has seriously mental disease. 4. Uncontrolled clinically significant heart disease and Pulmonary dysfunction. 5. Pregnancy or breast feeding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04425265 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04425265 currently recruiting?
Yes, NCT04425265 is actively recruiting participants. Contact the research team at chmingy@mail.sysu.edu.cn for enrollment information.
Where is the NCT04425265 trial being conducted?
This trial is being conducted at Guangzhou, China, Zhuhai, China, Nanchang, China.
Who is sponsoring the NCT04425265 clinical trial?
NCT04425265 is sponsored by Sun Yat-sen University. The trial plans to enroll 500 participants.